As of Friday, April 24, MiNK Therapeutics, Inc.’s INKT share price has surged by 7.23%, which has investors questioning if ...
Surveys have found water voles living in more streams in the moorland catchments of the Don and Holme rivers than previously ...
An investigational cocktail was tied to a 0% overall response rate in patients with gastroesophageal cancer, but developers ...
(Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) ...
First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients ...
Team insiders Ryan Mink and Garrett Downing sit down with Trey Hendrickson, Malaki Starks, Tavius Robinson and Justice Hill ...
Team insiders Ryan Mink and Garrett Downing sit down with Senior Vice President of Marketing Brad Downs to get the story ...
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE)-- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell ...
NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results